Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Pati...
2018年10月9日 - 9:30PM
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases with an initial focus on the development
of RP-G28, a drug candidate with the potential to be the first
FDA-approved treatment for lactose intolerance (LI), today
presented additional data from its previously completed Phase 2b
trial of RP-G28 exhibiting colonic microbiome adaptation and
improved lactose tolerance.
“These results are instrumental in understanding
the mode of action and effectiveness of RP-G28 in increasing the
abundance of gut microbes that are believed to rapidly metabolize
lactose, which, in turn, improves lactose tolerance and mitigates
the related gastric-based symptoms,” said M. Andrea Azcarate-Peril,
Ph.D., Associate Professor of Medicine and Director the Microbiome
Core at the University of North Carolina, Chapel Hill. “These
results are particularly encouraging as they correlate with similar
findings in an 85-subject Phase 2a study of RP-G28, providing us
with additional evidence of colonic adaptation with the
compound.”
Data from the poster, titled “A Novel
Galacto-Oligosaccharide (RP-G28) Promotes Beneficial Adaptations to
the Human Gut Microbiome in Patients with Lactose Intolerance,”
showed significant increases in several species of bacteria that
are associated with lactose metabolism in the active treatment
groups, compared to placebo. Notably, bifidobacteria increased in
77.7 percent of patients in the RP-G28 groups (p=<0.001).
Further, the poster identified that RP-G28 treatment resulted in
improved lactose tolerance and increased milk consumption two times
30 days following treatment, compared to placebo (p=0.014). The
data were presented at the Annual Scientific Meeting of the
American College of Gastroenterology in Philadelphia, Penn., and
the poster will be available on the company’s website:
http://www.ritterpharmaceuticals.com/investors/events-presentations.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.RitterPharma.com, @RitterPharma) develops novel therapeutic
products that modulate the gut microbiome to treat gastrointestinal
diseases. The Company’s lead product candidate, RP-G28, has the
potential to become the first FDA-approved treatment for lactose
intolerance, a condition that affects millions of people worldwide.
RP-G28 is in Phase 3 clinical development with its first Phase 3
study currently underway. The Company is further exploring the
therapeutic potential that gut microbiome changes may have on
treating/preventing a variety of diseases including:
gastrointestinal diseases, cancer, metabolic, and liver
disease.
Forward-Looking Statements
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that express the current beliefs and
expectations of Ritter Pharmaceuticals’ management. Any statements
contained herein that do not describe historical facts are
forward-looking statements that are subject to risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from those discussed in such
forward-looking statements. Factors that could affect our actual
results are included in the periodic reports on Form 10-K and Form
10-Q that we file with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date
hereof, and the Company undertakes no obligation to update or
revise the forward-looking statements, except as otherwise required
by law, whether as a result of new information, future events or
otherwise.
Contacts
Investor Contact:
John Beck
310-203-1000
john@ritterpharma.com
Media Contact:
Jules Abraham
CoreIR
917-885-7378
julesa@coreir.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024